Business
PRTC Presents LYT-100 Data at ATS Conference
PRTC Presents LYT-100 Data at ATS Conference.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n 16 May 2022\n \n \n \n \n \n \n \n \n \n PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022\n \n \n \n \n \n \n \n \n \n Further data from Phase 1 study in healthy older adults demonstrate improved tolerability profile of LYT-100 compared to pirfenidone\n \n \n \n \n \n \n \n \n \n Data support the planned LYT-100 dose-ranging registration-enabling studies in\n \n \n idiopathic pulmonary fibrosis\n \n \n , with topline results expected in 2023\n \n \n \n \n \n PureTech Health plc\n \n (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of additional data for PureTech's LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference. The data were shared in a scientific poster session and detailed the outcomes of a study in healthy older adults showing that LYT-100 demonstrated a lower incidence of adverse events (AEs) compared to pirfenidone at comparable exposure levels. Key outcomes of this study that are supportive of the observed improved tolerability of LYT-100\n \n were reported\n \n in January 2022. The data support the upcoming registration-enabling studies in which PureTech plans to investigate LYT-100 in patients with idiopathic pulmonary fibrosis (IPF) at the planned 550 mg three times daily dose (TID) as well as a dose with a higher total drug exposure than the currently approved dose of pirfenidone to evaluate if higher exposure could translate into improved efficacy.\n \n \n \n \n \n Pirfenidone is approved by the U.S. Food and Drug Administration (FDA) for the treatment of IPF but is associated with significant tolerability issues that LYT-100, as a deuterated form of pirfenidone, is intended to reduce. PureTech intends to advance LYT-100 into late-stage clinical development for the treatment of IPF using a 505(b)(2) development path, beginning with a dose-ranging study evaluating six months of treatment with LYT-100 with topline results expected by the end of 2023. \n \n \n \n \n \n \"Although approved antifibrotics for the treatment of IPF delay the progression of lung fibrosis and increas...